Houlihan Lokey stock hits all-time high at 201.84 USD

Houlihan Lokey (HLI) stock recently reached an all-time high of $201.84, driven by robust financial performance including a 32.68% 1-year gain and 23.3% revenue growth. The investment bank reported strong Q1 FY26 adjusted EPS of $2.14, surpassing analyst expectations of $1.68 by 27.38%. Despite these positive results, the stock experienced a minor decline during regular trading hours, yet the company's consistent outperformance and analyst price targets ranging from $166 to $232 continue to attract investor attention.

Analysis

Houlihan Lokey (HLI) has reached a new all-time high of $201.84, propelled by robust fundamental performance and strong investor confidence. The company's financial health is underscored by a 23.3% revenue growth rate and a 32.68% stock price increase over the past year. This momentum is further substantiated by its first fiscal quarter 2026 results, where adjusted EPS of $2.14 significantly beat analyst expectations of $1.68 by 27.38%. However, valuation metrics suggest caution; the stock trades at a high P/E ratio of 32.37 and is noted to be above its fair value according to InvestingPro analysis. Despite the strong earnings surprise, the stock experienced a minor decline, indicating that the positive results may have already been priced in during its run-up to the new high. The wide analyst price target range of $166 to $232 further reflects this tension between proven performance and a rich valuation.

Key Decisions for Investors

• Investors should weigh the company's demonstrated fundamental strength, including a significant earnings beat and strong revenue growth, against its elevated valuation at a P/E of 32.37, which may limit near-term upside.
• The minor stock decline following a strong earnings report suggests a 'sell the news' reaction or that positive expectations were fully priced in, warranting caution for new positions at this all-time high.
• Given the stock is trading above its fair value estimate but within a wide analyst target range ($166-$232), it is prudent to monitor for either a consolidation phase that could present a more attractive entry point or a break above the current range on new catalysts.